Industry reports
Editor highlights

Cetuximab Research Reports, April 2014

You might be interested in: cancer, biosimilar, colorectal cancer, more »


 

1-7 of 7 reports for Cetuximab
Cetuximab - Key patent, SPC, and data exclusivity expiry (7 country coverage)

Cetuximab - Key patent, SPC, and data exclusivity expiry (7 country coverage)

  • $ 460
  • Industry report
  • March 2014
  • by GenericsWeb

... cetuximab - key patent, spc, and data exclusivity expiry (7 country coverage) pipeline selector helps you avoid hours of painstaking reserach by quickly providing you with an accurate snapshot ...

Cetuximab - Key patent, SPC, and data exclusivity expiry (44 countries coverage)

Cetuximab - Key patent, SPC, and data exclusivity expiry (44 countries coverage)

  • $ 1 105
  • Industry report
  • March 2014
  • by GenericsWeb

... cetuximab - key patent, spc, and data exclusivity expiry (44 countries coverage) pipeline selector helps you avoid hours of painstaking reserach by quickly providing you with an accurate snapshot ...

Cetuximab  - Comprehensive patent search

Cetuximab - Comprehensive patent search

  • $ 8 250
  • Company report
  • March 2014
  • by GenericsWeb

... But delivers categorisation and interpretation, all delivered by a convenient online interface. The pipeline developer report covers cetuximabcetuximab indications: colorectal cancer; squamous cell ...

Cetuximab - Key patent, SPC, and data exclusivity expiry (7 country coverage), GenericsWeb - Selector 7

Cetuximab - Key patent, SPC, and data exclusivity expiry (7 country coverage), GenericsWeb - Selector 7

  • $ 500
  • Company report
  • March 2014
  • by GenericsWeb - Selector 7

... Selector report covers cetuximabcetuximab indications: colorectal cancer; advanced squamous cell carcinoma of the head and neckcetuximab innovator: imclone (erbitux)examples of information ...

Cetuximab - Key patent, SPC, and data exclusivity expiry (44 country coverage), Generics Web - Selector 44

Cetuximab - Key patent, SPC, and data exclusivity expiry (44 country coverage), Generics Web - Selector 44

  • $ 1 200
  • Company report
  • March 2014
  • by Generics Web - Selector 44

... Selector report covers cetuximabcetuximab indications: colorectal cancer; advanced squamous cell carcinoma of the head and neckcetuximab innovator: imclone (erbitux)examples of information ...

Market and Product Forecasts: Top 20 Oncology Therapy Brands 2011-21 - Avastin fails to top any individual market in 2011

Market and Product Forecasts: Top 20 Oncology Therapy Brands 2011-21 - Avastin fails to top any individual market in 2011

  • $ 11 400
  • Industry report
  • September 2012
  • by Datamonitor

... Gleevec (imatinib; novartis) - forecast assumptions - gleevec forecast 2011-21 Revlimid (lenalidomide; celgene) - forecast assumptions - revlimid forecast 2011-21 Erbitux (cetuximab; eli ...

Product Profiles: Targeted Cancer Therapies - Patient selection driving novel drug approvals

Product Profiles: Targeted Cancer Therapies - Patient selection driving novel drug approvals

  • $ 11 400
  • Industry report
  • August 2012
  • by Datamonitor

... Erbitux (cetuximab; eli lilly/bristol-myers squibb/merck kgaa) - drug profile - development overview - swot analysis - product positioning - clinical and commercial attractiveness ...




ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.